ClinicalTrials.gg
CompletedNCT01825200Updated Feb 18, 2015Results posted

Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age

A Phase 3 interventional study of Flublok and Afluria in Influenza, sponsored by Protein Sciences Corporation. Completed at 14 sites in United States. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-02-18.

Sponsored by Protein Sciences Corporation · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,640
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing FluBlok in Influenza, Human — none open to participants now, none under way, none of them phase 3. FluBlok · Influenza, Human.

Enrollment
2nd of 11
2,640 · median 606
Started
2013
the only one that year
Phase 3
3 of 11
none open now
Registered
6th of 11
by date
Lead sponsor
3 of 11
Protein Sciences Corporation

Among the 11 studies testing FluBlok in Influenza, Human, this one is the 2nd largest by enrollment, is the only one that started in 2013, is one of 3 in phase 3, and was the 6th registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

None of the 11 studies testing FluBlok in Influenza, Human is open now. The open studies under Influenza, Human, anywhere →

Where they have run

About FluBlok

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing FluBlok in Influenza, Human as a file.
02

Study summary

The hypothesis for this trial is that the incidence of a pre-defined composite of common systemic hypersensitivity adverse events for Flublok recipients is non-inferior to that reported for licensed IIV recipients. Another hypothesis is that the safety and reactogenicity of Flublok is clinically acceptable, i.e. consistent with the overall safety profiles previously observed with Flublok and with the licensed comparator.

Read the detailed description

The Advisory Committee on Immunization Practices (ACIP) recommends that all people aged 6 months and older be immunized to prevent influenza. Currently the only approved influenza vaccine across the entire age group is inactivated influenza vaccine (IIV). A Biologics Licensing Application (BLA) for Flublok was approved by the FDA for influenza immunization of adults 18-49 years of age. Additional safety and, ultimately efficacy, data is needed to support use in adults ≥50 years of age, an important age group as adults ≥65 years of age are among those at increased risk of influenza complications.

03

Conditions studied

  • Influenza

Browse trials for

Keywords

  • Influenza
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ambulatory adults aged 50 years and older
  2. Medically stable, as determined by medical history and targeted physical examination based on medical history, if appropriate
  3. Able to understand and comply with planned study procedures
  4. Provides written prior to initiation of any study procedure.

Exclusion criteria

Exclusion Criteria:

  1. Known to either study vaccine (see product package inserts)
  2. Receipt of any other influenza or other vaccine within 30 days prior to enrollment in this study.
  3. Receipt of any new medication within 30 days prior to enrollment in this study
  4. Plans to participate in any investigation involving an product during this study.
  5. Pre-existence of atopic dermatitis or any other cutaneous disorder that could complicate the evaluation of potential primary endpoints.
  6. Any clinical or social circumstance that in the opinion of the investigator could interfere with compliance with study procedures or interfere with the interpretation of clinical data.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
2,640 participants (actual)

Study arms

  • Active comparator
    Flublok

    Flublok containing 3x45µg (135µg total) of recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and influenza B viruses in a total volume of 0.5 mL

    Biological: Flublok

  • Placebo comparator
    Afluria

    Afluria, containing 3x15µg (45µg total), of trivalent, inactivated influenza vaccine (licensed IIV) containing influenza antigen derived from A/H1N1 and A/H3N2 and influenza B viruses in a total volume of 0.5 mL

    Biological: Afluria

Interventions

  • BiologicalFlublok

    A Biologics Licensing Application (BLA) for Flublok was approved by the FDA for influenza immunization of adults 18-49 years of age. Flublok is produced using recombinant technology under serum-free conditions.

  • BiologicalAfluria

    Afluria is approved for use in persons 5 years of age and older and is produced by inactivation and disruption of live influenza virus grown in embryonated chicken eggs.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Common Hypersensitivity Reactions as Measure of Safety

    Number of participants who experience a pre-defined common systemic hypersensitivity adverse event, including rash, urticaria, swelling or edema through Day 30 post-vaccine administration.

    Time frame: 30 Days

Secondary outcomes

  1. Subjects With at Least One Unsolicited Adverse Event in the 30 Days Following Vaccine Administration

    Subjects with at least one serious adverse event and subjects with at least one medically-attended unsolicited adverse event occurring during the 30 days following vaccine administration

    Time frame: 30 Days

  2. Number of Participants With Local and Systemic Events Reported as a Measure of Safety

    Number of solicited local and systemic events of reactogenicity reported with the help of a memory aid during the seven days following vaccine administration.

    Time frame: 7 Days

  3. Subjects With at Least One Hypersensitivity Event Reported on Day 0 and Days 0-7 Following Vaccine Administration as a Measure of Safety

    Subjects with at least one pre-defined common systemic hypersensitivity adverse event, including rash, urticaria, swelling or non-dependent edema on Day 0 and for Days 0 to 7 following vaccine administration

    Time frame: 7 Days

07

Results

Posted Feb 18, 2015
Limitations and caveats
Rash, urticaria, swelling and edema were self-reported by subjects and most were not observed by investigators. Review by independent experts indicated that 42 of 52 subject-reported events did not represent Type 1 (IgE-mediated) hypersensitivity.

Participant flow

Subjects were recruited at outpatient medical clinics over a period of five weeks.

Participant flow — Overall Study
MilestoneFlublokAfluria
Started13191321
Completed13141314
Not completed57
Withdrew: Lost to follow-up56
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryNumber of Participants With Common Hypersensitivity Reactions as Measure of Safety

Number of participants who experience a pre-defined common systemic hypersensitivity adverse event, including rash, urticaria, swelling or edema through Day 30 post-vaccine administration.

Time frame:
30 Days
Reported as:
Number · participants
Number of Participants With Common Hypersensitivity Reactions as Measure of Safety
participantsFlublokAfluria
Number of Participants With Common Hypersensitivity Reactions as Measure of Safety3121
SecondarySubjects With at Least One Unsolicited Adverse Event in the 30 Days Following Vaccine Administration

Subjects with at least one serious adverse event and subjects with at least one medically-attended unsolicited adverse event occurring during the 30 days following vaccine administration

Time frame:
30 Days
Reported as:
Number · participants
Subjects With at Least One Unsolicited Adverse Event in the 30 Days Following Vaccine Administration
participantsFlublokAfluria
Serious Adverse Events (SAEs)510
Medically-Attended Unsolicited Adverse Events5351
SecondaryNumber of Participants With Local and Systemic Events Reported as a Measure of Safety

Number of solicited local and systemic events of reactogenicity reported with the help of a memory aid during the seven days following vaccine administration.

Time frame:
7 Days
Reported as:
Number · participants
Number of Participants With Local and Systemic Events Reported as a Measure of Safety
participantsFlublokAfluria
Number of Participants With Local and Systemic Events Reported as a Measure of Safety432480
SecondarySubjects With at Least One Hypersensitivity Event Reported on Day 0 and Days 0-7 Following Vaccine Administration as a Measure of Safety

Subjects with at least one pre-defined common systemic hypersensitivity adverse event, including rash, urticaria, swelling or non-dependent edema on Day 0 and for Days 0 to 7 following vaccine administration

Time frame:
7 Days
Reported as:
Number · participants
Subjects With at Least One Hypersensitivity Event Reported on Day 0 and Days 0-7 Following Vaccine Administration as a Measure of Safety
participantsFlublokAfluria
Day 053
Days 0-72512

Adverse events

Collected over 30 days following vaccine administration. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Flublok—5/1,314 (0.4%)20/1,314 (1.5%)
Afluria—10/1,313 (0.8%)16/1,313 (1.2%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventFlublokAfluria
SepsisInfections and infestations0/13142/1313
Myocardial InfarctionCardiac disorders1/13142/1313
Cerebellar Stroke SyndromeNervous system disorders0/13141/1313
Diabetic KetoacidosisEndocrine disorders0/13141/1313
Alcoholic HepatitisInjury, poisoning and procedural complications1/13141/1313
Leg FractureInjury, poisoning and procedural complications0/13141/1313
PneumoniaInfections and infestations0/13141/1313
HypertensionCardiac disorders0/13141/1313
AppendicitisInfections and infestations0/13141/1313
Prostate CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/13140/1313
Most frequent other events
Most frequent other events
EventFlublokAfluria
HeadacheNervous system disorders8/131412/1313
DiarrheaGastrointestinal disorders12/13144/1313

Baseline characteristics

The primary analysis population includes all randomized subjects who received a dose of study vaccine and for whom some safety data were available after administration of vaccine. Subjects were analyzed according to the vaccine received, regardless of whether this was the treatment group to which they were randomized.

Age, Continuous
Age, Continuous(years)FlublokAfluriaTotal
Mean64 (50 to 99)64 (50 to 93)64 (50 to 99)
Age, Categorical
Age, Categorical(Participants)FlublokAfluriaTotal
<=18 years000
Between 18 and 65 years6726651337
>=65 years6426481290
Sex: Female, Male
Sex: Female, Male(Participants)FlublokAfluriaTotal
Female7307251455
Male5845881172
Race (NIH/OMB)
Race (NIH/OMB)(Participants)FlublokAfluriaTotal
American Indian or Alaska Native8614
Asian7512
Native Hawaiian or Other Pacific Islander123
Black or African American197212409
White109810832181
More than one race358
Unknown or Not Reported000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)FlublokAfluriaTotal
Hispanic or Latino10599204
Not Hispanic or Latino120912142423
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)FlublokAfluriaTotal
United States131413132627
08

Study locations

14 sites
  • Genova Clinical Research
    Tucson, Arizona 85704-1152, United States
  • Clinical Research of South Florida
    Coral Gables, Florida 33134, United States
  • Meridian Clinical Research
    Savannah, Georgia 31406, United States
  • Heartland Research Associates, LLC
    Wichita, Kansas 67207, United States
  • Benchmark Research
    Metairie, Louisiana 70006, United States
  • Maine Research Associates, LLC
    Auburn, Maine 04210, United States
  • Meridian Clinical Research
    Omaha, Nebraska 68164, United States
  • Clinical Research Center of Nevada, LLC
    Las Vegas, Nevada 89104, United States
  • Regional Clinical Research
    Binghamton, New York 13901, United States
  • Wake Research
    Raleigh, North Carolina 27612, United States
  • Rapid Medical Research, Inc.
    Cleveland, Ohio 44122, United States
  • Research Across America
    Dallas, Texas 75234, United States
  • Benchmark Research
    Fort Worth, Texas 76135, United States
  • Benchmark Research
    San Angelo, Texas 76904, United States
09

References and documents

Publications

  • Izikson R, Leffell DJ, Bock SA, Patriarca PA, Post P, Dunkle LM, Cox MM. Randomized comparison of the safety of Flublok((R)) versus licensed inactivated influenza vaccine in healthy, medically stable adults >/= 50 years of age. Vaccine. 2015 Nov 27;33(48):6622-8. doi: 10.1016/j.vaccine.2015.10.097. Epub 2015 Nov 1. PubMed 26529070 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2015, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2013
First posted
Apr 5, 2013
Start
Mar 2013
Primary completionActual
May 2013
CompletionActual
May 2013
Results first posted
Feb 18, 2015
Last update
Feb 18, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01825200
Lead sponsor
Protein Sciences Corporation
Responsible party
Sponsor
First posted
Apr 5, 2013
Start date
Mar 2013
Primary completion
May 2013
Completion
May 2013
Results posted
Feb 18, 2015
Last update
Feb 18, 2015

Study contacts

Brandon Essink, MD
principal investigator · Meridian Clinical Research
Paul Bradley, MD
principal investigator · Meridian Clinical Research
William Seger, MD
principal investigator · Benchmark Research
Darrell Herrington, DO
principal investigator · Benchmark Research
George Bauer, MD
principal investigator · Benchmark Research
Frank Eder, MD
principal investigator · Regional Clinical Research
Treva Tyson, MD
principal investigator · Wake Research
Bob Weiss, MD
principal investigator · Maine Research Associates, LLC
Jeffrey Rosen, MD
principal investigator · Clinical Research of South Florida
Joe Blumenau, MD
principal investigator · Research Across America
Steven Folkerth, MD
principal investigator · Clinical Research Center of Nevada, LLC
Leah Schmidt, DO
principal investigator · Genova Clinical Research
Eric Sheldon
principal investigator · Miami Research Associates
Alan C. Wine, MD
principal investigator · Rapid Medical Research, Inc.
Terry Poling, MD
principal investigator · Heartland Research Associates, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: FluBlok

Start the discussion